Walleye Capital’s Alaunos Therapeutics TCRT Stock Holding History

Walleye Capital’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-79	Closed	-$30K	–	1100
2020 Q3	$30K	Buy	+79	New	+$34.9K	﹤0.01%	778

Other funds holding TCRT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Walleye Capital's TCRT Position: Q4 2020 in Review

Walleye Capital sold out of Alaunos Therapeutics (TCRT) in Q4 2020, closing a stake of 79 shares — an estimated $30K sold.

Walleye Capital first reported a position in TCRT in Q3 2020 and held it in 1 quarter. The position peaked at $30K in Q3 2020. 156 funds tracked by Wall St. Rank hold TCRT as of Q4 2020.

Walleye Capital reported no remaining Alaunos Therapeutics position as of Q4 2020 after selling out during the quarter.
Walleye Capital sold 79 Alaunos Therapeutics shares in Q4 2020, an estimated $30K.
Walleye Capital first reported a position in Alaunos Therapeutics in Q3 2020 and held it in 1 quarter.
Walleye Capital's Alaunos Therapeutics position peaked at $30K in Q3 2020.
156 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2020.

Based on Walleye Capital's 13F filing for Q4 2020, filed 16 Feb 2021.